Elevated Plasma T-LAK cell-originated protein kinase Owned the Potential for Predicting Favorable Outcomes in Acute Ischemic Stroke Patients Authors: Lingzhi Li, Ziping Han, Tong Shen, Zhenhong Yang, Junfen Fan, Rongliang Wang, Yangmin Zheng, Haiping Zhao, Qingfeng Ma, Yumin Luo Published: 2026 ABSTRACT AbstractT-lymphokine-activated killer-cell-originated protein kinase (TOPK), was widely overexpressed in various malignant tumors, and played critical roles in their growth, differentiation and metastasis. However, its levels and potential clinical significance in acute ischemic stroke (AIS) was unknown. We detected the plasma TOPK protein level and mRNA level of neutrophilic TOPK in AIS patients using ELISA and RT-PCR, and analyzed their association with functional outcomes statistically. Among 330 patients with AIS, plasma TOPK concentrations differed significantly between patients present with excellent outcomes or not at 3 months. Plasma TOPK ≥ 69.95 pg/mL independently predicted excellent functional outcomes. In the subgroup of patients received rt-PA treatment, patients with TOPK ≥ 69.95 pg/ml also predicted excellent functional outcomes. Addition of plasma TOPK to clinical predictors for excellent outcomes post AIS as well as outcomes after rt-PA treatment improved their reclassification and discrimination. Although TOPK mRNA levels were significantly elevated in the neutrophils of AIS patients, no significant predictive value was observed for excellent outcomes. Conclusively, higher plasma TOPK levels (especially TOPK ≥ 69.95 pg/ml) might emerge as a prognostic indicator for the 3-month excellent functional outcomes post AIS and possessed predictive value in identifying patients with 3-month excellent functional outcomes after rt-PA treatment.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1007/s10571-026-01765-z.Keywords: Acute ischemic stroke (AIS), Modified rankin scale (mRS), rt-PA intravenous thrombolysis, T-LAK cell-originated protein kinase (TOPK), Neutrophil, Logistic regression analysis Introduction T-lymphokine-activated killer-cell-originated protein kinase (TOPK), also known as PDZ-binding kinase (PBK), was a mitogen-activated serine/threonine protein kinase that was widely overexpressed in highly proliferative cells especially in malignancies (Sun et al. 2022; Qi et al. 2025; Herbert et al. 2018; Dimond et al. 2025; Zhao et al. 2026). It was activated via phosphorylation by JAK2, p59-FYN, glucocorticoid-inducible kinase 3 (SGK3), and others in a cell cycle-dependent manner and functioned to promote proliferation and inhibit apoptosis via acting on different signal pathways including TRIM37/NF-κB axis, YB1/Eef1a1, tumor necrosis factor alpha-induced protein-8 like 2 (TIPE2), AMPK-mediated phosphorylation of ULK1 and others (Han et al. 2021; Ma et al. 2022; Wang et al. 2022a, b, 2025; Xiao et al. 2022; Peng et al. 2023; Shu et al. 2023; Wu et al. 2023; Zhang et al. 2025). Mounting pre-clinical evidence supported TOPK’s critical role in the growth, differentiation and metastasis of various malignant tumors, including leukemia and myeloma, among others (Matsuo et al. 2014; Joel et al. 2015; Ma et al. 2021). Moreover, the upregulation of TOPK helped in cancer diagnosis and predicted progression and prognosis for treatment such as immunotherapy (Ikeda et al. 2016; Ohashi et al. 2017; Thanindratarn et al. 2020, 2021; Lee et al. 2022; Chen et al. 2026; Zang et al. 2026), thus great progress had been made in the discovery and development of small molecule inhibitors targeting TOPK (including HI-TOPK-032, OTS514, Worenine and others), as well as in considering future clinical therapeutic potential in cancer treatment (Huang et al. 2021; Yang et al. 2022; Zeng et al. 2023, 2024; Lu et al. 2024; Zhang et al. 2024; Li et al. 2025). However, deeper basic and more clinical research was urgent to carry out in order to provide supporting evidence for clinical application. Despite recent advances in recanalization therapies, ischemic stroke (IS) remained the leading cause of disability and mortality worldwide (Collaborators 2022). Accumulating preclinical evidence had revealed the function and molecular mechanism of TOPK in neuroprotection following IS (Zhao et al. 2013, 2014a, b; Han et al. 2018). Microarray analysis of the ipsilateral cortices in experimental rat stroke models revealed that TOPK was the most differentially upregulated gene among the MAPK family members after cerebral ischemia (Zhao et al. 2013). Pre-clinical studies had reported that TOPK protected against focal cerebral ischemia/reperfusion injury in an experimental stroke model by antioxidation partly via activating the ERK pathway (Zhao et al. 2014b). Additionally, the antioxidative effects of TOPK/Akt contributed to the neuroprotection of ischemic post-conditioning treatment in experimental stroke models (Zhao et al. 2014a). Neuroinflammation was a crucial factor in the pathogenesis of central nervous system disorders, previous study demonstrated that TOPK promoted microglia/macrophage M2 polarization by regulating HDAC1/2 activity in an experimental mouse stroke model (Han et al. 2018). Mechanically, Zeng et al. also reported that TOPK modulated the expression of neutrophils chemokines via activating transcription factors STAT3 and NF-κB p65 in keratinocyte, thereby promoting neutrophils infiltration and psoriasis progression; knockout of TOPK or specific inhibitors in keratinocytes suppressed neutrophils infiltration and attenuated psoriatic inflammation, providing new insights into psoriasis treatment (Zeng et al. 2024). However, the expression pattern of TOPK in plasma and neutrophils of ischemic stroke patients, as well as their potential clinical relevance with functional outcome was yet to be addressed. Thus in this study, we aimed to detect TOPK in plasm and neutrophils of patients with acute ischemic stroke (including those patients receiving rt-PA intravenous thrombolytic therapy) and to evaluate the prognostic significance of TOPK expression levels in functional outcome post acute ischemic stroke (AIS), as well as post rt-PA intravenous thrombolytic therapy, thereby to assess its potential as an independent prognostic indicator for AIS, as well as for those receiving rt-PA thrombolysis. Methods To explore the expression pattern of TOPK in AIS, we detected plasma TOPK protein levels in AIS patients including those received rt-PA thrombolytic treatment, and further evaluated its potential prognostic significance for excellent outcomes 3 months post AIS. Subsequently, TOPK mRNA levels in peripheral neutrophils were preliminarily detected to analyze how TOPK overexpression contributes to excellent outcomes in patients with AIS. Study Population This study was approved by the Research Ethics Committee Review Board of Xuanwu Hospital, Capital Medical University (registration no. ChiCTR-NCT-03577093) and adhered to the principles of the Declaration of Helsinki. Written, informed consent for the collection of blood sample and clinical data was obtained from all enrolled individuals or their legal representatives. To evaluate its clinical significance, the plasma TOPK protein level was detected in 330 AIS patients’ samples from our biobank (https://www.clinicaltrials.gov; unique identifier: NCT03577093). The inclusion and exclusion criteria of the study population were described previously (Li et al. 2023). All included patients in the emergency department underwent blood sampling as soon as possible upon admission (within 30 min from admission) before rt-PA thrombolysis (onset-to sampling time was nearly equal to onset-to treatment time). TOPK mRNA levels were firstly detected in the peripheral neutrophils of a set of AIS patients (n = 27) recruited from the stroke center and matched healthy volunteers (n = 17) recruited from the medical examination center of Xuanwu Hospital. Then mRNA levels of neutrophilic TOPK were detected in a subset of 124 AIS patients with available peripheral neutrophil specimens. Clinical Assessment and Outcome Baseline variables were collected through neurologic examinations and clinical interviews conducted by board-certified neurologists. Stroke severity was assessed upon admission using the NIH Stroke Scale (NIHSS) (Lyden et al. 1994). Stroke etiology was defined according to the Trial of ORG 10,172 in the Acute Stroke Treatment (TOAST) classification (Adams et al. 1993). Functional outcomes were evaluated using the modified Rankin Scale (mRS) (van Swieten et al. 1988) at 3 months through face-to-face visits or telephone interviews conducted by trained neurologists. The primary outcome was excellent outcomes defined as mRS 0–1 at 3 months, or equal to the mRS pre-stroke. All participants and investigators involved in this study were blinded to the TOPK measurements. TOPK Measurements Blood samples were stored as described in our previous study (Li et al. 2023). Plasma TOPK levels were measured using the quantitative competitive sandwich enzyme-linked immunosorbent assay (ELISA), according to the instruction of the manufacturer (cat. no. abx382074, Abbexa LTD, Cambridge, UK). ELISA was conducted as previously described, however, the intra-assay coefficient of variation was < 5.5%, and that of the inter-assay < 9.4% (Zhang et al. 2024). Neutrophilic TOPK mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR), which was performed as previously described (Zeng et al. 2024; Shen et al. 2025). Briefly, total RNA was extracted from neutrophil samples using the TRIzol Reagent (cat.no. 15596026, Invitrogen) and quantified with nanodrop. 1 µg of total RNA in a final volume of 20µL was used for reverse transcription with Hifair® II 1st Strand cDNA Synthesis Kit (cat.no. 11121ES60; Yeasen, China, ). Total cDNA was then prepared for RT-PCR with the Hieff® PCR SYBR Green Master Mix (cat.no. 11202ES08; Yeasen, China). GAPDH was used as the control. The primer sequences used in the present study (Sangon Biotech, Shanghai, China) were listed in Table S1. The 2−ΔΔCT method was used for relative quantification of mRNA expression. Each quantitative PCR assay was performed in triplicate by a professional technician blinded to the clinical assessment and outcomes. Statistical Analysis All the data were analyzed with SPSS 26 (SPSS Inc., Chicago, Illinois), GraphPad Prism 8.4.0 (GraphPad Software, La Jolla, California), and R studio 3.6.1 (Boston, Massachusetts). p < 0.05 was regarded as statistical significance. The normality of data distribution was accessed using the Shapiro-Wilk test (for sample size < 50) and Kolmogorov–Smirnov test (for sample size ≥ 50). Depending on the nature of data distributions, the continuous variables were analyzed with the Student t-test or Mann–Whitney U test, and categorical variables were analyzed using the Pearson χ2 test or Fisher exact test. We evaluated the relationship between two variables using Pearson or Spearman correlation coefficient. Univariate logistic regression analysis was conducted to examine the association between TOPK and stroke outcomes as previously performed (Ma et al. 2023). TOPK was cut off by the Youden index into categorical variable. Subsequently, multivariate logistic regression analysis was employed to assess the association between TOPK and the stroke outcomes. Baseline clinical variables including age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, neutrophil-to-lymphocyte ratio, and platelet count, were entered as confounders to the multivariate analysis of the functional outcome at 3 months of all patients with AIS. Additionally, age, sex, admission NIHSS score, atrial fibrillation, small vessel occlusion stroke and platelet count were counted as confounders in the multivariate analysis for the 3-months functional outcome, specifically in patients who received rt-PA treatment. Crude odds ratios (ORs), adjusted ORs and the corresponding 95% confidence intervals (CIs) for TOPK were calculated. We quantified the improvement in discrimination and reclassification in the predictive models by adding TOPK using continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indexes. Based on the observed difference in plasma TOPK levels between patients with excellent (mRS 0–1) and non-excellent (mRS 2–6) functional outcomes at 3 months (mean difference = 15.2pg/mL, pooled SD = 28.5pg/mL, effect size Cohen’s d = 0.53), and assuming a two-sided significance level (α) of 0.05, our sample of 330 AIS patients provided > 90% statistical power (actual power = 0.94) to detect a significant association between TOPK levels and functional outcomes. Furthermore, for logistic regression analysis with 7 candidate predictors (including TOPK, age, baseline NIHSS, etc.), the current sample size (n = 330) met the recommended criterion of at least 10 events per variable (EPV). With 126 patients (38.2%) achieving excellent outcomes, the EPV was approximately 18, which exceeds the minimum requirement of 10, supporting the stability and reliability of our multivariable model. Results Patient Characteristics and Clinical Variables TOPK levels were measured in 330 plasma specimens from patients with AIS. Among the 330 patients, the mean ± SD age was 64.0 ± 9.0 years, and 89 (27.0%) were female. The median NIHSS score on admission was 6 (Interquartile range 3, 12), and the median time from stroke onset to treatment was 3.0 (1.5-5.0) hours. Of the patients enrolled, 113 (34.2%) received intravenous rt-PA thrombolysis, 28 (8.5%) received endovascular treatment, and 173 (64.9%) had an excellent outcome at 3 months (Table 1). Among the various clinical and laboratory parameters outlined in Table 1, several factors were associated with an excellent functional outcome for patients. These factors included a younger age (63.0 [55.0, 71.0] vs. 66.0 [57.0, 77.0], p = 0.012, for patients presenting with an excellent functional outcome and those without), a lower incidence of coronary heart disease (13.9 vs. 26.1%, p = 0.008), atrial fibrillation (10.4 vs. 21.7%, p = 0.008). Additionally, a lower admission NIHSS score (3.0 [2.0, 6.0] vs. 10.0 [6.0, 16.0], p < 0.001), a shorter onset-to-treatment time (2.7 [1.4, 4.0] vs. 3.1 [1.6, 6.1], p = 0.040), and a higher proportion of intravenous thrombolysis (41.0 vs. 26.8%, p = 0.009) were observed. Furthermore, a lower incidence of endovascular treatment (4.0 vs. 13.4%, p = 0.005) and a higher prevalence of small vessel occlusion (29.5 vs. 17.2%, p = 0.013) were observed. Other significant factors included a lower serum glucose level (6.9 [6.1, 8.0] vs. 7.3 [6.9, 8.8], p = 0.018), a higher lymphocyte count (1.7 [1.2, 2.2] vs. 1.5 [1.0, 2.0], p = 0.001), a lower neutrophil-to-lymphocyte ratio (NLR) (2.7 [2.0, 4.5] vs. 3.5 [2.1, 7.0], p = 0.008), and a higher platelet count (215.0 [182.0, 249.0] vs. 202.0 [164.0, 234.0], p = 0.007) at 3 months. Table 1Baseline characteristics of the whole study population according to the modified Rankin Scale (mRS) at 3 months (n = 330)TotalExcellent outcomebp Value(N = 330)Present (N = 173)Absent (N = 157)Demographic characteristicsAge, y, mean (SD)64.0 [56.0, 73.0]63.0 [55.0, 71.0]66.0 [57.0, 77.0]0.012aFemale sex (%)89 (27.0)45 (26.0)44 (28.0)0.774BMI, kg/m2, median [IQR]25.4 [23.5, 27.4]25.4 [23.3, 27.2]25.8 [23.7, 27.4]0.742Medical historyHypertension218 (66.1)113 (65.3)105 (66.9)0.855Diabetes mellitus118 (35.8)57 (32.9)61 (38.9)0.316Hyperlipemia86 (26.1)49 (28.3)37 (23.6)0.391Coronary heart disease65 (19.7)24 (13.9)41 (26.1)0.008aAtrial fibrillation52 (15.8)18 (10.4)34 (21.7)0.008aRecurrent stroke97 (29.4)52 (30.1)45 (28.7)0.875Smoking habit82 (24.8)48 (27.7)34 (21.7)0.250Stroke characteristics and treatmentAdmission NIHSS score6.0 [3.0, 12.0]3.0 [2.0, 6.0]10.0 [6.0, 16.0]< 0.001aOnset-to-treatment time, h3.0 [1.5, 5.0]2.7 [1.4, 4.0]3.1 [1.6, 6.1]0.040aIntravenous thrombolysis113 (34.2)71 (41.0)42 (26.8)0.009aEndovascular treatment28 (8.5)7 (4.0)21 (13.4)0.005aStroke etiology (TOAST), n (%)Large artery atherosclerosis170 (51.5)85 (49.1)85 (54.1)0.424Small vessel occlusion78 (23.6)51 (29.5)27 (17.2)0.013aCardioembolic25 (7.6)8 (4.6)17 (10.8)0.055Other determined10 (3.0)5 (2.9)5 (3.2)-Undetermined47 (14.2)24 (13.9)23 (14.6)0.965Posterior circulation stroke43 (13.0)24 (13.9)19 (12.1)0.754Clinical and laboratory findingsSystolic blood pressure, mm Hg150.0 [140.0, 164.0]150.0 [140.0, 162.0]150.0 [140.0, 165.0]0.937Diastolic blood pressure, mm Hg85.0 [77.0, 91.0]85.0 [77.0, 92.0]86.0 [78.0, 90.0]0.945Serum glucose, mmol/L7.2 [6.3, 8.4]6.9 [6.1, 8.0]7.3 [6.9, 8.8]0.018aHbA1c, %6.0 [6.0, 6.0]6.0 [5.9, 6.0]6.0 [6.0, 6.1]0.356Neutrophil count, ×1,000/mm35.0 [3.9, 6.6]5.3 [4.0, 6.9]4.8 [3.9, 6.3]0.126Lymphocyte count, ×1,000/mm31.6 [1.2, 2.2]1.7 [1.2, 2.2]1.5 [1.0, 2.0]0.001aNLR3.0 [2.1, 5.2]2.7 [2.0, 4.5]3.5 [2.1, 7.0]0.008aPlatelet count, ×1,000/mm3207.0 [173.2, 243.5]215.0 [182.0, 249.0]202.0 [164.0, 234.0]0.007aHYC, µmol/L14.6 [14.4, 14.7]14.6 [14.4, 15.6]14.6 [14.4, 14.6]0.409TG, mmol/L1.5 [1.0, 2.5]1.4 [0.9, 2.3]1.6 [1.0, 2.6]0.160TC, mmol/L4.5 [3.8, 5.3]4.5 [3.8, 5.2]4.4 [3.8, 5.4]0.650HDL, mmol/L1.2 [1.0, 1.4]1.2 [1.0, 1.4]1.1 [0.9, 1.4]0.089LDL, mmol/L2.7 [2.0, 3.4]2.7 [2.1, 3.4]2.5 [1.9, 3.3]0.395Biological measuresPBK, pg/ml99.7 [48.2, 475.0]128.2 [54.7, 620.9]67.7 [45.3, 338.1]0.010aBMI = Body Mass Index; HbA1c = HemoglobinA1c; HDL = High density lipoprotein; HYC = Homocysteine; LDL = Low density lipoprotein; mRS = modified Rankin Scale; NE = Neutrophil elastase; NIHSS = NIH Stroke Scale; NLR = Neutrophil-to-Lymphocyte Ratio; rtPA = recombinant tissue plasminogen activator; TC = Total cholesterol; TG = Triglyceride; TOAST = Trial of ORG 10,172 in Acute Stroke Treatment; PBK = PDZ-binding kinaseData for continuous variables are described as mean (SD) (normally distributed variables) or as median [interquartile range] (nonnormally distributed variables), for categorical variables are described as n (%)ap < 0.05bThe excellent outcome was defined as an mRS score ≤ 1 or equal to prestroke mRS Baseline characteristics of the whole study population according to the modified Rankin Scale (mRS) at 3 months (n = 330) BMI = Body Mass Index; HbA1c = HemoglobinA1c; HDL = High density lipoprotein; HYC = Homocysteine; LDL = Low density lipoprotein; mRS = modified Rankin Scale; NE = Neutrophil elastase; NIHSS = NIH Stroke Scale; NLR = Neutrophil-to-Lymphocyte Ratio; rtPA = recombinant tissue plasminogen activator; TC = Total cholesterol; TG = Triglyceride; TOAST = Trial of ORG 10,172 in Acute Stroke Treatment; PBK = PDZ-binding kinase Data for continuous variables are described as mean (SD) (normally distributed variables) or as median [interquartile range] (nonnormally distributed variables), for categorical variables are described as n (%) ap < 0.05 bThe excellent outcome was defined as an mRS score ≤ 1 or equal to prestroke mRS Plasma TOPK Predicted the Functional Outcome at 3 Months Post AIS In the overall study population, significant differences in plasma TOPK concentrations (128.2 [54.7, 620.9] vs. 67.7 [45.3, 338.1], pg/mL, p = 0.010) were observed between patients with and without excellent outcomes at 3 months (128.2 [54.7, 620.9] vs. 67.7 [45.3, 338.1] pg/mL, p = 0.010) (Table 1). After adjusting for clinical variables including age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, NLR, and platelet count, multivariable logistic regression analyses indicated that the adjusted OR [95% CIs] for plasma TOPK levels (each 10 pg/mL increase) was 1.005 [1.000–1.009], p = 0.046 (Table 2). Table 2PBK and the risk of primary outcome after AIS (n = 330)Model 1bModel 2cOR (95% CI)p valueOR (95% CI)p valuePBK, per 10 pg/ml increase1.002 (0.999–1.005)0.2551.005 (1.000-1.009)0.046aPBK > 69.65 pg/ml2.282 (1.462–3.560)< 0.001a2.918 (1.741–4.889)< 0.001aPBK = PDZ-binding kinaseap < 0.05bModel 1 was an unadjusted logistic regression model with the PBKcModel 2 was an adjusted logistic regression model. The variables in model 2 for excellent outcome included age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, neutrophil-to-lymphocyte ratio, platelet count, and PBK concentration on admission PBK and the risk of primary outcome after AIS (n = 330) PBK = PDZ-binding kinase ap < 0.05 bModel 1 was an unadjusted logistic regression model with the PBK cModel 2 was an adjusted logistic regression model. The variables in model 2 for excellent outcome included age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, neutrophil-to-lymphocyte ratio, platelet count, and PBK concentration on admission Based on the receiver operating characteristic curve, the optimal cut-off point for TOPK was 69.65 pg/mL, with 64.8% sensitivity and 61.9% specificity for predicting excellent outcomes at 3 months. Then the TOPK was dichotomized by the optimal cut-off point into a categorical variable, TOPK ≥ 69.95 pg/mL (OR = 2.282 [1.462–3.560], p < 0.001) was independently predictive of the excellent functional outcome at 3 months. After adjustment with the clinical variables, the multivariable logistic regression analyses demonstrated that TOPK ≥ 69.95 pg/mL (OR = 2.918 [1.741–4.889], p < 0.001) remained an independent predictor of the excellent outcome 3 months following AIS (Table 2). The incrementally predictive value of plasma TOPK levels for excellent outcomes following AIS was verified by improving both the reclassification and discrimination of the clinical predictive models. Adding the categorical TOPK to the clinical variables improved their net reclassification (NRI% = 41.23 [20.23–62.23], p < 0.001), and the integrated discriminatory ability (IDI% = 3.31[0.78–5.84], p = 0.010) (Table 3). Table 3Reclassification of the outcomes by PBK among AIS patients (n = 330)NRIIDIEstimate (95% CI), %p valueEstimate (95% CI), %p valueClinical model for excellent outcomebReference–Reference–Clinical modelb + PBKc41.23 (20.23–62.23)< 0.001a3.31 (0.78–5.84)0.010aIDI = Integrated discrimination improvement; NRI = Net reclassification improvement; PBK = PDZ-binding kinaseap < 0.05bThe variables in clinical model for excellent outcome included age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, neutrophil-to-lymphocyte ratio, and platelet countcAs a categorical variable Reclassification of the outcomes by PBK among AIS patients (n = 330) IDI = Integrated discrimination improvement; NRI = Net reclassification improvement; PBK = PDZ-binding kinase ap < 0.05 bThe variables in clinical model for excellent outcome included age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, neutrophil-to-lymphocyte ratio, and platelet count cAs a categorical variable Plasma TOPK Predicted an Excellent Outcome at 3 Months After rt-PA Treatment Of the study population, 113 received rt-PA treatment without bridging. In this subgroup, 62.8% of patients had excellent functional outcomes 3 months after rt-PA treatment. Unadjusted logistic regression indicated that TOPK ≥ 69.95 pg/mL (OR = 2.990 [1.356–6.592], p = 0.007) independently predicted the excellent outcome at 3 months. After adjustment for various clinical variables, including age, sex, admission NIHSS score, atrial fibrillation, small vessel occlusion stroke, and platelet count, the multivariable logistic regression analyses confirmed TOPK ≥ 69.95 pg/mL (OR = 3.435 [1.315–8.972], p = 0.012) as an independent predictor of the excellent outcome 3 months following rt-PA treatment (Table 4). Furthermore, the inclusion of plasma TOPK to the clinical variables enhanced the integrated discriminatory ability (IDI% = 4.85 [0.38–9.32], p = 0.033) of the clinical predictive model, and net reclassification (NRI% = 53.39 [16.56–90.22], p = 0.005) (Table 5). Table 4PBK and the excellent outcome of rtPA treatment after AIS (n = 113)Model 1bModel 2cOR (95% CI)p valueOR (95% CI)p valuePBK > 69.65 ng/ml2.990 (1.356–6.592)0.007a3.435 (1.315–8.972)0.012aTOPK = T-LAK-cell-originated protein kinaseap < 0.05bModel 1 was an unadjusted logistic regression model with the PBKcModel 2 was an adjusted logistic regression model. The variables in model 2 for excellent outcome included age, sex, admission NIHSS score, atrial fibrillation, small vessel occlusion stroke, platelet count, and PBK concentration on admission PBK and the excellent outcome of rtPA treatment after AIS (n = 113) TOPK = T-LAK-cell-originated protein kinase ap < 0.05 bModel 1 was an unadjusted logistic regression model with the PBK cModel 2 was an adjusted logistic regression model. The variables in model 2 for excellent outcome included age, sex, admission NIHSS score, atrial fibrillation, small vessel occlusion stroke, platelet count, and PBK concentration on admission Table 5Reclassification of the outcomes by PBK among AIS patients received rtPA treatment (n = 113)NRIIDIEstimate (95% CI), %p valueEstimate (95% CI), %p valueClinical model for excellent outcomebReference–Reference–Clinical modelb + PBKc53.39 (16.56–90.22)0.005a4.85 (0.38–9.32)0.033aIDI = Integrated discrimination improvement; NRI = Net reclassification improvement; PBK = PDZ-binding kinaseap < 0.05bThe variables in clinical model for excellent outcome included age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, neutrophil-to-lymphocyte ratio, and platelet countcAs a categorical variable Reclassification of the outcomes by PBK among AIS patients received rtPA treatment (n = 113) IDI = Integrated discrimination improvement; NRI = Net reclassification improvement; PBK = PDZ-binding kinase ap < 0.05 bThe variables in clinical model for excellent outcome included age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, neutrophil-to-lymphocyte ratio, and platelet count cAs a categorical variable Neutrophilic TOPK Negatively Correlated with Neutrophil Count and Increased in Older Adult Patients with AIS Above data suggested that plasma TOPK was a prognostic biomarker for excellent outcomes 3 months post AIS. Besides, increasing plasma TOPK concentrations were significantly correlated with increasing neutrophil counts (ρ = 0.13, p = 0.016) and increasing NLR (ρ = 0.13, p = 0.015) in the whole study population (Fig. S1B). To explore how TOPK overexpression contributes to excellent outcomes in patients with AIS, we preliminarily detected the mRNA levels in the neutrophils of patients with AIS and healthy volunteers. We then analyzed the relationship between neutrophilic TOPK levels and functional outcomes to investigate whether TOPK contributed to the link between peripheral neutrophilia observed after ischemic stroke and the functional outcome of patients with AIS. We firstly detected the mRNA levels of TOPK in the peripheral neutrophils collected from patients with AIS and matched controls. The TOPK levels were significantly elevated in the neutrophils of patients with AIS compared to controls (Fig. 1A, p = 0.024). The mRNA levels of neutrophilic TOPK were further measured in a subgroup of patients with AIS for whom specimens were available (n = 124). In this subgroup, the neutrophilic TOPK mRNA level was negatively associated with the circulating neutrophil counts (ρ =-0.37, p < 0.001) and NLR (ρ =-0.28, p < 0.001) (Fig. 1D), the neutrophilic TOPK mRNA level (0.73 [0.64, 0.95] vs. 0.49 [0.33, 0.76], p = 0.030) was higher in old AIS patients (≥ 80 years) than that in young patients (65–70 years) (Fig. 1B). Analysis of neutrophilic TOPK mRNA level in AIS patients. A Neutrophilic TOPK mRNA level in AIS patients (n = 27) and matched controls (n = 17); B Neutrophilic TOPK mRNA level in the young AIS patients (65–70 years, n = 36) and the old AIS patients (≥ 80 years, n = 11); C Neutrophilic TOPK mRNA level according to the outcome in AIS patients (n = 124); D Association of neutrophilic TOPK mRNA level with neutrophil counts and NLR in the AIS patients (n = 124). ρ represented the Spearman correlation coefficient In this subgroup, 59.7% of the patients had excellent functional outcomes at 3 months (n = 74). Neutrophilic TOPK mRNA levels (0.62 [0.36, 0.95] vs. 0.58 [0.37, 0.85], p = 0.531) did not differ significantly between patients with and without excellent outcomes (Fig. 1C). Unadjusted logistic regression analyses indicated that the OR for neutrophilic TOPK levels was 1.511 [0.680–3.354], p = 0.311. After adjusting for clinical variables, including age, sex, admission NIHSS score, and onset-to-treatment time, logistic regression analyses indicated that the adjusted OR for neutrophilic TOPK levels was 1.165 [0.403–3.370], p = 0.778 (Table S2). The optimal cut-off point for neutrophilic TOPK of 0.33 had 82.9% sensitivity and 25% specificity to predict excellent outcomes at 3 months. As a categorical variable, the OR of neutrophilic TOPK ≥ 0.33 for predicting excellent outcomes at 3 months was 1.615 [0.667–3.914], p = 0.288, with an adjusted OR for categorical neutrophilic TOPK levels of 0.921 [0.271–3.124], p = 0.894 (Table S2). The above results suggested that higher plasma TOPK in AIS patients owned the potential as an independent predictor for an excellent functional outcome at 3 months follow-up, the same went for those received intravenous rt-PA thrombolysis, however, this warranted confirmation in larger prospective cohorts. Discussion Increasing evidence had identified TOPK as an effective therapeutic target for treatment of various cancers (Lee et al. 2022; Lu et al. 2024; Chen et al. 2026; Zang et al. 2026). Recent research also found that TOPK was upregulated in proliferative smooth muscle cells within pulmonary arteries, pharmacological inhibitor of TOPK were identified as effective reversal strategies in pulmonary arterial hypertension, providing translational significance (Bordan et al. 2024). Accumulating preclinical evidence had revealed the upregulation of TOPK in experimental models of cerebral ischemia, moreover, TOPK protected against focal cerebral ischemia/reperfusion injury by antioxidation and promoting microglia/macrophage M2 polarization mechanismly (Zhao et al. 2013, 2014a, b; Han et al. 2018). Zeng et al. also reported that TOPK modulated neutrophils infiltration via influencing the expression of neutrophils chemokines (Zeng et al. 2024). These studies all provided new insights into the significant roles that TOPK played in AIS. However, the expression pattern of TOPK in plasma and neutrophils of ischemic stroke patients, as well as their potential clinical relevance with functional outcome was yet to be addressed. Thus in this study, we detected TOPK in plasm and neutrophils of patients with acute ischemic stroke (including those patients received rt-PA intravenous thrombolytic therapy) and investigated the association between plasma TOPK levels and excellent functional outcomes 3-months after AIS in order to demonstrated its potential as a biomarker to predict prognosis following AIS. Patients with increased plasma TOPK levels at admission were likelier to experience excellent outcomes at 3 months. Notably, we found that patients receiving rt-PA treatment with increased plasma TOPK levels pretreatment were expected to have 3-month excellent outcomes compared to patients without such elevated levels. Specifically, the plasma TOPK concentration ≥ 69.95 pg/mL independently predicted the excellent outcome of patients with AIS, with an additional 2.282-fold possibility of having an excellent outcome and an additional 2.918-fold possibility of having an excellent functional outcome after adjustment for co-founders. For patients receiving rt-PA treatment, plasma TOPK concentration ≥ 69.95 pg/mL was predicted to have an additional 2.990-fold possibility of having an excellent outcome and an additional 3.435-fold possibility of having an excellent functional outcome after adjustment for co-founders. Moreover, the addition of TOPK to the clinical models for predicting the 3-month excellent functional outcome after AIS and rt-PA treatment significantly enhanced prediction efficiency. In contrast, neutrophilic TOPK mRNA levels showed no significant correlation with functional outcomes, nor did they improve the predicting efficiency of the clinical model. The plasma TOPK level was positively associated with neutrophil count and NLR, but the neutrophilic TOPK mRNA level was negatively correlated with neutrophil count and NLR. However, it was noted that these correlations warranted further confirmation with prospective, multi-center cohorts. TOPK was a MAPKK-like kinase that facilitated cell cycle regulation and mitotic progression (Han et al. 2021). It was over-expressed in various tumors and associated with poor clinical outcomes (Matsuo et al. 2014; Joel et al. 2015; Huang et al. 2021; Thanindratarn et al. 2021). Mounting pre-clinical and clinical studies had highlighted the role of TOPK as a prognostic biomarker and therapeutic target in cancers (Zlobec et al. 2010; Shih et al. 2012; Wei et al. 2012; Lei et al. 2015; Koh et al. 2018; Kruthika et al. 2019). Ischemia was also a pathological process that stimulated cell proliferation and recent pre-clinical studies had recognized the involvement of TOPK in ischemic injury. In ischemic stroke, TOPK was crucial in protecting against ischemia and focal cerebral ischemia/reperfusion injury through anti-oxidative and anti-inflammatory effects (Zhao et al. 2014a, b). Consistent with the neuroprotective effects of TOPK in the pre-clinical investigation, the study here suggested that higher plasma TOPK (≥ 69.95 pg/mL) was associated with the excellent outcome of patients with AIS and supported the positive clinical role of TOPK in ischemic stroke. Pre-clinical evidence suggested that TOPK positively correlated with microglia/macrophage M2 polarization and exerted anti-inflammation effects after cerebral ischemia (Han et al. 2018; Zeng et al. 2024). We also measured the relationship between TOPK and interleukins in the plasma, which was observed positively correlated with the anti-inflammatory cytokines IL-2 as well as IL-10, and negatively correlated with the pro-inflammatory cytokine IL-16 (Fig. S1). These results indicated that human plasma TOPK may also be involved in the inflammatory response post AIS. Overexpression of TOPK was exclusive to proliferative cells, being suppressed in differentiated and mature cells, and TOPK mRNA expression was barely detectable in normal peripheral blood cells (Nandi et al. 2004). Compared to healthy controls, TOPK was up-regulated in the neutrophils of patients with AIS, indicating the existence of a proliferative neutrophil subpopulation in ischemic stroke. Reminiscent of the high TOPK expression in human promyelocytic leukemia HL-60 cells as well (Liu et al. 2012), an immature neutrophil population may also exist in the peripheral blood of patients with AIS. Numerous clinical studies had demonstrated that an increased neutrophil count was associated with worse functional outcome (Maestrini et al. 2015; Zhu et al. 2018; Boisseau et al. 2019; Ferro et al. 2021). We also observed that neutrophilic TOPK mRNA levels were negatively associated with neutrophil count and NLR. This finding somewhat supported the favorable prognostic role of TOPK in AIS. It may be explained by the evidence that TOPK was strongly down-regulated during the terminal differentiation of neutrophil, and TOPK expression was minimal in differentiated cells (Nandi et al. 2004). Notably, neutrophilic TOPK mRNA levels were increased in older adult patients. Cerebral ischemia-elicited tissue injury activated strong myeloid-biased hematopoiesis in the bone marrow, giving rise to the observed neutrophilia in the peripheral blood of mice (Courties et al. 2015). Additionally, aging altered the features of the immune system; some molecules associated with aging were known to increase myelopoiesis (Rossi et al. 2005; Maryanovich et al. 2018; Ross et al. 2024). Therefore, TOPK levels may be linked to aging-associated neutrophils in patients with AIS. This study filled the gap in understanding the clinical role of TOPK and introduced the prognostic value of TOPK in ischemic stroke to the existing literature. Patients with AIS with a higher plasma TOPK level on admission may be more likely to achieve a favorable outcome in clinical practice. The plasma TOPK level could also aid doctors in determining the effect of rt-PA treatment. TOPK was vital in ischemic post-conditioning (IPostC)-mediated neuroprotection (Zhao et al. 2014a). In the future, plasma TOPK may be a predictive candidate for the stratification of the treatment effect of IPostC. However, the prognostic significance of plasma TOPK in patients with AIS as well as those received rt-PA thrombolytic treatment warranted confirmation with more basic investigations and prospective multicenter cohort with larger samples as well. Nevertheless, the present study had limitations. First, despite adjusting for multiple potential confounders, including age, sex, admission NIHSS score, onset-to-treatment time, coronary heart disease, atrial fibrillation, intravenous thrombolysis, endovascular treatment, small vessel occlusion stroke, serum glucose, NLR, and platelet count, possible residual confounding factors cannot be excluded. Second, the association between plasma TOPK level and the 3-month functional outcome of AIS was preliminarily analyzed in a single center with a limited sample size. Prospective multicenter cohort with larger samples was needed to confirm the predictive potential of TOPK in AIS in future. Third, we had demonstrated in the present study that TOPK was up-regulated in the peripheral neutrophils of patients with AIS. Moreover, our previous study had indicated the increased expression and increased phosphorylation of TOPK in neurons of the ischemic rat brain (Zhao et al. 2014b). However, they can not determine the origin for plasma TOPK in patients with AIS, which need to be elucidated with further studies. Finally, the temporal changes in plasma TOPK level after the onset of AIS, especially pre- and post-rt-PA treatment, warranted further follow-up study. Conclusions In summary, increasing evidence had identified TOPK as an effective therapeutic target for treatment of various cancers. Experimental research also revealed the upregulation of TOPK in experimental models of cerebral ischemia, moreover, TOPK protected against focal cerebral ischemia/reperfusion injury by antioxidation and promoting microglia/macrophage M2 polarization mechanically. These studies all provided insights into the significant roles that TOPK played in AIS. Investigating the expression pattern of TOPK in AIS patients, ae well as their potential clinical relevance with functional outcome might provide a prognostic predictor for AIS. This study demonstrated that higher plasma TOPK levels, but not neutrophilic TOPK levels, were associated with better functional outcomes post AIS. This made plasma TOPK emerge as a prognostic indicator for the 3-month excellent functional outcomes post AIS and possess predictive value in identifying patients with 3-month excellent functional outcomes after rt-PA treatment as well. The expression characteristics of neutrophilic TOPK in AIS may reflect its function in myelocytes, exploring its prognostic roles in AIS warranted further studies in depth. However, the prognostic significance of plasma TOPK in patients with AIS as well as those received rt-PA thrombolytic treatment warranted confirmation with more basic investigations and prospective multicenter cohort with larger samples as well. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Author Contributions Yumin Luo and Qingfeng Ma conceived the study. Tong Shen, Zhenhong Yang, Junfen Fan, Rongliang Wang, Yangmin Zheng and Haiping Zhao collected samples and recruited patients. Lingzhi Li and Ziping Han participated in the statistical analysis and wrote the paper. All authors read and approved the final manuscript. Funding The work was supported by grants from the National Natural Science Foundation of China (81971222 and 82171298) and Zhejiang Provincial Natural Science Foundation of China (No. LQN25H090005). Data Availability No datasets were generated or analysed during the current study. Declarations Competing Interests The authors declare no competing interests. Consent for Publication Not applicable. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Lingzhi Li and Ziping Han have contributed equally to this work. Contributor Information Qingfeng Ma, Email: maqf@xwhosp.org. Yumin Luo, Email: yumin111@ccmu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement No datasets were generated or analysed during the current study.